news
Concizumab haemophilia trials paused over safety concerns
The occurrence of non-fatal thrombotic events in Phase III study participants has called into question the safety of concizumab.
List view / Grid view
haemophilia
Filter the results
news
Sanofi to acquire haemophilia specialists Bioverativ for $11.6bn
Sanofi and Bioverativ Inc., have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ...
news
Microcapsules to enhance the efficiency of genome-editing
Researchers have found that polymer and hybrid silica-coated microcapsules are efficient in genome-editing...
article
Shire on Haemophilia: How to treat a bleeding disorder
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
news
UCL Technology Fund invests £1m in gene therapy company, Freeline
20 June 2016 | By Victoria White, Digital Content Producer
Freeline is developing and commercialising gene therapies for bleeding and other life threatening or debilitating disorders...
news
EC approves Alprolix for the treatment of haemophilia B
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
news
Biogen announces plans to spin off its haemophilia business
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
news
Battle set for the European haemophilia B treatment market, says GlobalData
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...